Companies Cano Health
Cano Health CEO salary & total pay, FY2022: $4.3M
Cano Health (CANO) CEO salary, fiscal 2022: Marlow Hernandez was paid a salary of $350,000 and $4,320,007 in total compensation. Free brief. Every figure links to the company’s own filing.
Cano Health no longer files a proxy statement; its last pay data is FY2022.
Marlow Hernandez's complete compensation dossier
A PDF and a CSV sent to your email: Marlow Hernandez's pay in every fiscal year Cano Health reported it, line by line, with Marlow Hernandez's equity grants and Cano Health's disclosed peer group where the company discloses them. Every row is cited to its filing.
See an example →CEO pay, last three years
- $1,052,808FY2020
- $31,685,996FY2021
- $4,320,007FY2022
CEO total pay was $4,320,007 in fiscal 2022, down from $31,685,996 in fiscal 2021.
FY2022: salary $350,000 · bonus $0 · stock awards $3,421,127 · option awards $539,999
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Marlow Hernandez | $350,000 | $0 | $3,421,127 | $539,999 | $0 | $0 | $8,881 | $4,320,007 |
| Chief Executive Officer | ||||||||
| Robert Camerlinck | 468,623 | 0 | 3,187,382 | 44,798 | 0 | 0 | 2,882 | 3,703,685 |
| Chief Operating Officer | ||||||||
| Brian Koppy | 325,000 | 0 | 953,723 | 142,322 | 0 | 0 | 8,900 | 1,429,945 |
| Chief Financial Officer | ||||||||
| Richard Aguilar | 300,000 | 0 | 919,032 | 144,802 | 0 | 0 | 0 | 1,363,834 |
| Chief Clinical Officer | ||||||||
| David Armstrong | 235,000 | 0 | 687,981 | 108,601 | 0 | 0 | 8,969 | 1,040,551 |
| Chief Compliance Officer and General Counsel | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2022 total | FY2021 total | FY2020 total | Δ FY2021→2022 |
|---|---|---|---|---|
| Marlow Hernandez | $4,320,007 | $31,685,996 | $1,052,808 | ↓ −27,365,989 |
| Robert Camerlinck | 3,703,685 | — | — | — |
| Brian Koppy | 1,429,945 | 10,518,124 | — | ↓ −9,088,179 |
| Richard Aguilar | 1,363,834 | 10,076,489 | 350,000 | ↓ −8,712,655 |
| David Armstrong | 1,040,551 | 7,714,038 | 325,880 | ↓ −6,673,487 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive compensation philosophy is focused on pay-for-performance. In this regard, we link a significant portion of each NEO's target TDC to the achievement of specified performance goals or appreciation in the market price of our common stock.
| CEO STI target (% of salary) | 50% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | FW Cook |
| Clawback policy | true |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2022
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Marlow Hernandez | RSU | 2022-03-15 | — | — | 567,351 | — | $3,421,127 |
| Robert Camerlinck | OPTION | 2022-03-15 | — | — | 11,546 | — | 44,798 |
| Richard Aguilar | RSU | 2022-03-15 | — | — | 152,410 | — | 919,032 |
| Richard Aguilar | OPTION | 2022-03-15 | — | — | 37,320 | — | 144,802 |
| Marlow Hernandez | OPTION | 2022-03-15 | — | — | 139,175 | — | 539,999 |
| Robert Camerlinck | RSU | 2022-08-10 | — | — | 250,000 | — | 1,185,000 |
| David Armstrong | RSU | 2022-03-15 | — | — | 114,093 | — | 687,981 |
| David Armstrong | OPTION | 2022-03-15 | — | — | 27,990 | — | 108,601 |
| Robert Camerlinck | RSU | 2022-03-15 | — | — | 332,070 | — | 2,002,382 |
| Brian Koppy | RSU | 2022-03-15 | — | — | 158,163 | — | 953,723 |
| Brian Koppy | OPTION | 2022-03-15 | — | — | 36,681 | — | 142,322 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Marlow Hernandez | $3,421,127 | $0 | $539,999 | 0.0% |
| Robert Camerlinck | 3,187,382 | 0 | 44,798 | 0.0% |
| Richard Aguilar | 919,032 | 0 | 144,802 | 0.0% |
| David Armstrong | 687,981 | 0 | 108,601 | 0.0% |
| Brian Koppy | 953,723 | 0 | 142,322 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2022
| Executive | Award | Exercisable | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|---|
| Richard Aguilar | Option | — | 600,700 | 14.75 | — |
| Richard Aguilar | RSU | — | 150,000 | — | 205,500 |
| Richard Aguilar | RSU | — | 214,000 | — | 293,180 |
| Richard Aguilar | Option | — | 37,320 | 6.03 | — |
| Richard Aguilar | RSU | — | 85,821 | — | 117,575 |
| Brian Koppy | RSU | — | 280,479 | — | 384,256 |
| Brian Koppy | Option | — | 400,000 | 14.75 | — |
| Brian Koppy | RSU | — | 142,500 | — | 195,225 |
| Brian Koppy | Option | — | 36,681 | 6.03 | — |
| Brian Koppy | RSU | — | 90,640 | — | 124,177 |
| David Armstrong | Option | — | 600,700 | 14.75 | — |
| David Armstrong | RSU | — | 37,500 | — | 51,375 |
| David Armstrong | RSU | — | 214,000 | — | 293,180 |
| David Armstrong | Option | — | 27,990 | 6.03 | — |
| David Armstrong | RSU | — | 62,737 | — | 85,950 |
| Hernandez | Option | — | 2,820,000 | 14.75 | — |
| Hernandez | RSU | — | 1,004,625 | — | 1,376,336 |
| Hernandez | Option | — | 139,175 | 6.03 | — |
| Hernandez | RSU | — | 312,210 | — | 427,728 |
| Hernandez | RSU | — | 1,004,625 | — | 1,376,336 |
| Hernandez | Option | — | 139,175 | 6.03 | — |
| Hernandez | RSU | — | 312,210 | — | 427,728 |
| Richard Aguilar | RSU | — | 150,000 | — | 205,500 |
| Richard Aguilar | RSU | — | 214,000 | — | 293,180 |
| Richard Aguilar | Option | — | 37,320 | 6.03 | — |
| Richard Aguilar | RSU | — | 85,821 | — | 117,575 |
| Robert Camerlinck | Option | — | 600,700 | 14.75 | — |
| Robert Camerlinck | RSU | — | 214,000 | — | 293,180 |
| Robert Camerlinck | Option | — | 11,546 | 6.03 | — |
| Robert Camerlinck | RSU | — | 23,369 | — | 32,016 |
| Robert Camerlinck | RSU | — | 250,000 | — | 342,500 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Solomon D. TrujilloIndependent · Lead Independent Director · Nominating and Corporate Governance Committee · Compensation | $83,194 | $362,981 | $0 | — | $0 | $446,175 |
| Elliot CooperstoneNot independent | 48,937 | 327,980 | 0 | — | 0 | 376,917 |
| Jacqueline GuichelaarIndependent · Audit · Nominating and Corporate Governance Committee | 48,937 | 327,980 | 0 | — | 0 | 376,917 |
| Dr. Lewis GoldNot independent | 48,937 | 327,980 | 0 | — | 0 | 376,917 |
| Angel MoralesIndependent · Audit (Chair) · Compensation | 48,937 | 327,980 | 0 | — | 0 | 376,917 |
| Barry S. SternlichtNot independent | 48,937 | 327,980 | 0 | — | 0 | 376,917 |
| Kim RiveraIndependent · Audit · Nominating and Corporate Governance Committee (Chair) | 48,937 | 327,980 | 0 | — | 0 | 376,917 |
| Dr. Alan MuneyIndependent · Audit · Compensation (Chair) | 48,937 | 327,980 | 0 | — | 0 | 376,917 |
| Dr. Marlow HernandezEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $200,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | — |
| Stock ownership guideline | 5x annual cash retainer |
Total cost of the board
| Component | FY2022 |
|---|---|
| Cash retainers and fees | $425,753 |
| Equity awards (grant-date value) | $2,658,841 |
| All other compensation | $0 |
| Total cost of the board | $3,084,594 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Cano Health as a peer
Companies that benchmark against CANO
No companies currently name CANO as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Disclosed peer group — fiscal year 2022
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Apollo Medical Holdings | 2025 | Brandon Sim | $850,000 | $11,999,980 | $0 | $2,059,125 | $14,930,231 |
| 2 | Mednax (MD) | 2025 | Mark Ordan | 970,014 | 8,456,024 | 0 | 2,700,000 | 14,140,217 |
| 3 | The Ensign Group | 2025 | Barry Port | 549,264 | 2,912,355 | 0 | 10,317,247 | 13,804,700 |
| 4 | Addus HomeCare | 2025 | R. Dirk Allison | 1,076,923 | 9,767,870 | 0 | 1,320,000 | 12,190,449 |
| 5 | RadNet | 2025 | Howard Berger | 3,000,000 | 8,999,966 | 0 | 0 | 12,087,934 |
| 6 | Teladoc Health | 2025 | Charles Divita, III | 800,000 | 9,699,996 | 0 | 584,000 | 11,202,996 |
| 7 | Encompass Health | 2025 | Mark Tarr | 1,100,000 | 5,285,381 | 1,165,376 | 2,581,525 | 10,297,258 |
| 8 | Acadia Healthcare | 2025 | Christopher Hunter | 1,061,000 | 5,712,012 | 0 | 1,135,270 | 7,909,463 |
| 9 | Surgery Partners | 2025 | J. Eric Evans | 1,050,000 | 5,000,000 | 0 | 0 | 6,083,862 |
| 10 | U.S. Physical Therapy | 2025 | Christopher Reading | 1,003,125 | 1,955,250 | 0 | 1,506,375 | 4,468,314 |
| 11 | Cano Health | 2022 | Marlow Hernandez | 350,000 | 3,421,127 | 539,999 | 0 | 4,320,007 |
| 12 | National HealthCare | 2025 | Stephen Flatt | 577,000 | 505,215 | 300,481 | 1,280,000 | 2,685,370 |
| 13 | CorVel | 2026 | Michael Combs | 679,327 | 0 | 101,716 | 498,809 | 1,285,043 |
| — | 1Life Healthcare | — | — | — | — | — | — | not in coverage universe |
| — | Amedisys | — | — | — | — | — | — | not in coverage universe |
| — | Oak Street Health | — | — | — | — | — | — | not in coverage universe |
| — | LHC Group | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Cano Health | 0% | PSU 80 · Options 20 | Yes — Relative TSR | FW Cook |
| 1Life Healthcare | not disclosed | not disclosed | not disclosed | not disclosed |
| Acadia Healthcare | 85.6% | PSU 50 · RSU 50 | No | WTW |
| Addus HomeCare | not disclosed | Restricted Stock 100 | not disclosed | FW Cook |
| Amedisys | not disclosed | not disclosed | not disclosed | not disclosed |
| Apollo Medical Holdings | 193.8% | PSU 67 · RSU 33 | No | Pearl Meyer |
| CorVel | CEO: 75%, EVP Risk: 61%, CIO: 49%, VP Accounting: 28%% | not disclosed | No | not disclosed |
| Encompass Health | 173.8% | PSU 60 · RSU 20 · Options 20 | No | Pay Governance |
| LHC Group | not disclosed | not disclosed | not disclosed | not disclosed |
| Mednax (MD) | 180% | RSU 50 · PSU 50 | No | Semler Brossy Consulting Group |
| National HealthCare | not disclosed | not disclosed | not disclosed | false |
| Oak Street Health | not disclosed | not disclosed | not disclosed | not disclosed |
| RadNet | not disclosed | RSU 100 | No | Pearl Meyer |
| Surgery Partners | not disclosed | PSU 60 · Restricted Stock 40 | No | Frederic W. Cook & Co., Inc. (FW Cook) |
| Teladoc Health | 73% | RSU 50 · PSU 50 | No | Aon |
| The Ensign Group | not disclosed | not disclosed | not disclosed | Willis Towers Watson |
| U.S. Physical Therapy | not disclosed | not disclosed | not disclosed | Meridian Compensation Partners, LLC |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2023 | 2023-06-15 | 120,520,092 | 329,665,028 | 2,278,197 | 26.77% | Failed |
| 2022 | 2022-05-16 | 400,342,807 | 13,314,689 | 525,005 | 96.78% | Passed |
| 2021 | 2021-06-02 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2023 | 2023-06-15 | 26.77%a |
| 2022 | 2022-05-16 | 96.78%b |
| 2021 | 2021-06-02 | —c |
a. Approved under the standard stated in the filing — “The affirmative vote of a majority of the shares of common stock present or represented by proxy at the Annual Meeting and entitled to vote thereon is required to approve this proposal. || Abstentions: Abstentions and broker non-votes will have no effect on the outcome of the non-binding, advisory vote to approve the compensation of our named executive officers.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on the outcome of the non-binding, advisory vote to approve the compensation of our named executive officers.”.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 114 : 1 |
|---|---|
| CEO total compensation | $4,320,007 |
| Median employee compensation | $37,916 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2022 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Richard Aguilar | Chief Clinical Officer | 2023-05-25 | D | 600,000 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Aguilar | Chief Clinical Officer | 2023-05-25 | D | 600,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Aguilar | Chief Clinical Officer | 2023-05-25 | D | 675,940 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Aguilar | Chief Clinical Officer | 2023-05-25 | D | 675,940 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Aguilar | Chief Clinical Officer | 2023-05-25 | A | 600,000 | 0 | 0 | Common | Form 4 ↗ |
| Richard Aguilar | Chief Clinical Officer | 2023-05-25 | A | 675,940 | 0 | 0 | Common | Form 4 ↗ |
| Mark Novell | Chief Accounting Officer | 2023-05-31 | A | 60,502 | — | — | RSU | Form 4 ↗ |
| David Armstrong | See remarks | 2023-05-31 | A | 109,526 | — | — | RSU | Form 4 ↗ |
| Marlow Hernandez | Director | 2023-05-31 | A | 671,742 | — | — | RSU | Form 4 ↗ |
| Brian Koppy | Chief Financial Officer | 2023-05-31 | A | 248,226 | — | — | RSU | Form 4 ↗ |
| Richard Aguilar | Chief Clinical Officer | 2023-05-31 | A | 231,008 | — | — | RSU | Form 4 ↗ |
| Robert Camerlinck | Chief Operating Officer | 2023-05-31 | A | 239,139 | — | — | RSU | Form 4 ↗ |
| David Armstrong | See remarks | 2023-06-06 | D | 3,163 | 1 | 4,351 | Common | Form 4 ↗ |
| Richard Aguilar | Chief Clinical Officer | 2023-06-07 | D | 400,000 | 1 | 528,400 | Common | Form 4 ↗ |
| Richard Aguilar | Chief Clinical Officer | 2023-06-08 | D | 275,940 | 1 | 356,156 | Common | Form 4 ↗ |
| Richard Aguilar | Chief Clinical Officer | 2023-06-08 | A | 600,000 | 0 | 0 | Common | Form 4 ↗ |
| Richard Aguilar | Chief Clinical Officer | 2023-06-08 | D | 600,000 | 0 | 0 | Common | Form 4 ↗ |
| Richard Aguilar | Chief Clinical Officer | 2023-06-09 | D | 100,000 | 1 | 137,760 | Common | Form 4 ↗ |
| Richard Aguilar | Chief Clinical Officer | 2023-06-12 | D | 500,000 | 1 | 711,650 | Common | Form 4 ↗ |
| Jacqueline Guichelaar | Director | 2023-06-15 | A | 185,598 | — | — | Common | Form 4 ↗ |
| Angel Morales | Director | 2023-06-15 | A | 185,598 | — | — | Common | Form 4 ↗ |
| Dr. Alan Muney | Director | 2023-06-15 | A | 185,598 | — | — | Common | Form 4 ↗ |
| Kim Rivera | Director | 2023-06-15 | A | 185,598 | — | — | Common | Form 4 ↗ |
| Solomon D. Trujillo | Director | 2023-06-15 | A | 211,581 | — | — | Common | Form 4 ↗ |
| Richard Aguilar | Chief Clinical Officer | 2023-06-26 | D | 550,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Aguilar | Chief Clinical Officer | 2023-06-26 | D | 550,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Aguilar | Chief Clinical Officer | 2023-06-26 | A | 550,000 | 0 | 0 | Common | Form 4 ↗ |
| Richard Aguilar | Chief Clinical Officer | 2023-06-28 | D | 150,000 | 1 | 183,300 | Common | Form 4 ↗ |
| Richard Aguilar | Chief Clinical Officer | 2023-06-29 | D | 400,000 | 1 | 525,760 | Common | Form 4 ↗ |
| David Armstrong | See remarks | 2023-06-30 | A | 7,506 | 1 | 5,780 | Common | Form 4 ↗ |
| Marlow Hernandez | Director | 2023-07-12 | A | 189,681 | — | — | Common | Form 4 ↗ |
| Mark D. Kent | Interim CEO | 2023-07-12 | A | 1,138,088 | — | — | Common | Form 4 ↗ |
| Mark D. Kent | Interim CEO | 2023-07-12 | A | 216,237 | — | — | Common | Form 4 ↗ |
| Robert Camerlinck | Chief Operating Officer | 2023-08-11 | D | 30,646 | 1 | 23,453 | Common | Form 4 ↗ |
| Eladio Gil | Interim CFO | 2023-11-10 | A | 7,676 | 0 | 0 | RSU | Form 4 ↗ |
| Angel Morales | Director | 2023-11-20 | D | 69,685 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Angel Morales | Director | 2023-11-20 | D | 69,685 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Angel Morales | Director | 2023-11-20 | A | 69,685 | — | — | Common, indirect | Form 4 ↗ |
| Solomon D. Trujillo | Director | 2023-12-07 | A | 136,804 | — | — | Common | Form 4 ↗ |
| Solomon D. Trujillo | Director | 2023-12-07 | D | 136,804 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Solomon D. Trujillo | Director | 2023-12-07 | D | 136,804 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elliot Cooperstone | Greater-than-10% holder | 2023-12-15 | D | 532,603 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elliot Cooperstone | Greater-than-10% holder | 2023-12-15 | D | 532,603 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elliot Cooperstone | Greater-than-10% holder | 2023-12-15 | A | 532,603 | — | — | Common | Form 4 ↗ |
| Elliot Cooperstone | Greater-than-10% holder | 2023-12-21 | D | 82,843 | 6 | 469,430 | Common | Form 4 ↗ |
| Elliot Cooperstone | Greater-than-10% holder | 2023-12-21 | D | 6,309 | 7 | 41,765 | Common | Form 4 ↗ |
| Elliot Cooperstone | Greater-than-10% holder | 2023-12-22 | D | 27,377 | 6 | 154,787 | Common | Form 4 ↗ |
| Elliot Cooperstone | Greater-than-10% holder | 2023-12-26 | D | 21,154 | 5 | 115,124 | Common | Form 4 ↗ |
| Elliot Cooperstone | Greater-than-10% holder | 2023-12-27 | D | 37,607 | 6 | 212,370 | Common | Form 4 ↗ |
| Elliot Cooperstone | Greater-than-10% holder | 2023-12-28 | D | 41,197 | 6 | 247,227 | Common | Form 4 ↗ |
| Elliot Cooperstone | Greater-than-10% holder | 2023-12-29 | D | 35,112 | 6 | 210,644 | Common | Form 4 ↗ |
| Elliot Cooperstone | Greater-than-10% holder | 2024-01-02 | D | 43,505 | 5 | 235,658 | Common | Form 4 ↗ |
| Elliot Cooperstone | Greater-than-10% holder | 2024-01-03 | D | 24,182 | 5 | 119,423 | Common | Form 4 ↗ |
| Elliot Cooperstone | Greater-than-10% holder | 2024-01-03 | D | 50,818 | 4 | 207,251 | Common | Form 4 ↗ |
| Elliot Cooperstone | Greater-than-10% holder | 2024-01-04 | D | 13,328 | 4 | 53,297 | Common | Form 4 ↗ |
| Elliot Cooperstone | Greater-than-10% holder | 2024-01-05 | D | 25,000 | 4 | 96,233 | Common | Form 4 ↗ |
| Elliot Cooperstone | Greater-than-10% holder | 2024-01-08 | D | 25,000 | 4 | 95,553 | Common | Form 4 ↗ |
| Elliot Cooperstone | Greater-than-10% holder | 2024-01-09 | D | 25,000 | 4 | 93,673 | Common | Form 4 ↗ |
| Elliot Cooperstone | Greater-than-10% holder | 2024-01-10 | D | 25,000 | 4 | 93,293 | Common | Form 4 ↗ |
| Elliot Cooperstone | Greater-than-10% holder | 2024-01-11 | D | 25,000 | 4 | 89,790 | Common | Form 4 ↗ |
| Elliot Cooperstone | Greater-than-10% holder | 2024-01-12 | D | 1,065,206 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elliot Cooperstone | Greater-than-10% holder | 2024-01-12 | A | 1,065,206 | — | — | Common | Form 4 ↗ |
| Elliot Cooperstone | Greater-than-10% holder | 2024-01-12 | D | 24,171 | 3 | 79,878 | Common | Form 4 ↗ |
| Elliot Cooperstone | Greater-than-10% holder | 2024-01-12 | D | 1,065,206 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elliot Cooperstone | Greater-than-10% holder | 2024-01-17 | D | 5,987 | 3 | 17,489 | Common | Form 4 ↗ |
| Elliot Cooperstone | Greater-than-10% holder | 2024-01-17 | D | 94,013 | 2 | 214,058 | Common | Form 4 ↗ |
| Elliot Cooperstone | Greater-than-10% holder | 2024-01-18 | D | 100,000 | 2 | 191,250 | Common | Form 4 ↗ |
| Elliot Cooperstone | Greater-than-10% holder | 2024-01-22 | D | 125,000 | 3 | 312,763 | Common | Form 4 ↗ |
| Elliot Cooperstone | Greater-than-10% holder | 2024-01-23 | D | 73,034 | 3 | 214,800 | Common | Form 4 ↗ |
| Elliot Cooperstone | Greater-than-10% holder | 2024-01-24 | D | 35,808 | 3 | 101,612 | Common | Form 4 ↗ |
| Elliot Cooperstone | Greater-than-10% holder | 2024-01-25 | D | 18,569 | 3 | 47,960 | Common | Form 4 ↗ |
| Elliot Cooperstone | Greater-than-10% holder | 2024-01-26 | D | 32,693 | 3 | 89,736 | Common | Form 4 ↗ |
| Elliot Cooperstone | Greater-than-10% holder | 2024-01-29 | D | 41,357 | 3 | 113,471 | Common | Form 4 ↗ |
| Elliot Cooperstone | Greater-than-10% holder | 2024-01-30 | D | 12,703 | 3 | 34,285 | Common | Form 4 ↗ |
| Elliot Cooperstone | Greater-than-10% holder | 2024-01-31 | D | 8,935 | 3 | 23,177 | Common | Form 4 ↗ |
| Elliot Cooperstone | Greater-than-10% holder | 2024-02-01 | D | 1,100 | 3 | 2,780 | Common | Form 4 ↗ |
| Mark D. Kent | Director | 2024-06-28 | A | 94,416 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Eladio Gil | Interim CFO | 2024-06-28 | D | 7,676 | — | — | Common | Form 4 ↗ |
| Mark D. Kent | Director | 2024-06-28 | D | 1,749 | — | — | Common | Form 4 ↗ |
| Mark D. Kent | Director | 2024-06-28 | D | 23,609 | — | — | Common | Form 4 ↗ |
| Mark D. Kent | Director | 2024-06-28 | D | 23,609 | — | — | Common | Form 4 ↗ |
| Mark D. Kent | Director | 2024-06-28 | D | 45,995 | — | — | Common | Form 4 ↗ |
| Mark D. Kent | Director | 2024-06-28 | D | 15,296 | — | — | Common | Form 4 ↗ |
| Angel Morales | Director | 2024-06-28 | D | 2,485 | — | — | Common | Form 4 ↗ |
| Nut Tree Capital Management, LP | Greater-than-10% holder | 2024-06-28 | A | 17,054 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Nut Tree Capital Management, LP | Greater-than-10% holder | 2024-06-28 | A | 347,603 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Nut Tree Capital Management, LP | Greater-than-10% holder | 2024-06-28 | A | 32,750 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Nut Tree Capital Management, LP | Greater-than-10% holder | 2024-06-28 | A | 555,508 | — | — | Common, indirect | Form 4 ↗ |
| Nut Tree Capital Management, LP | Greater-than-10% holder | 2024-06-28 | A | 9,557,095 | — | — | Common, indirect | Form 4 ↗ |
| Robert Camerlinck | Chief Operating Officer | 2024-06-28 | D | 269,586 | — | — | Common | Form 4 ↗ |
| David Armstrong | See remarks | 2024-06-28 | A | 6,641 | — | — | Common | Form 4 ↗ |
| Solomon D. Trujillo | Director | 2024-06-28 | D | 3,782 | — | — | Common | Form 4 ↗ |
| Solomon D. Trujillo | Director | 2024-06-28 | D | 136,804 | — | — | Common | Form 4 ↗ |
| Dr. Alan Muney | Director | 2024-06-28 | D | 2,485 | — | — | Common | Form 4 ↗ |
| Angel Morales | Director | 2024-06-28 | D | 69,685 | — | — | Common, indirect | Form 4 ↗ |
| Kim Rivera | Director | 2024-06-28 | D | 2,485 | — | — | Common | Form 4 ↗ |
| Mark D. Kent | Director | 2024-06-28 | D | 1,749 | — | — | Common | Form 4 ↗ |
| Nut Tree Capital Management, LP | Greater-than-10% holder | 2024-06-28 | A | 912,538 | — | — | Common, indirect | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (143 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Marlow Hernandez. DEF 14A, filed 2023-05-22. Section “Executive Compensation Tables” · page 35. As printed: 4,320,007. View filing ↗
- Section 01, Robert Camerlinck. DEF 14A, filed 2023-05-22. Section “Executive Compensation Tables” · page 35. As printed: 3,703,685. View filing ↗
- Section 01, Brian Koppy. DEF 14A, filed 2023-05-22. Section “Executive Compensation Tables” · page 35. As printed: 1,429,945. View filing ↗
- Section 01, Richard Aguilar. DEF 14A, filed 2023-05-22. Section “Executive Compensation Tables” · page 35. As printed: 1,363,834. View filing ↗
- Section 01, David Armstrong. DEF 14A, filed 2023-05-22. Section “Executive Compensation Tables” · page 35. As printed: 1,040,551. View filing ↗
- Section 03, Marlow Hernandez RSU. DEF 14A, filed 2023-05-22. Section “Grants of Plan-Based Awards for Fiscal Year 2022” · grants of plan-based awards table. View filing ↗
- Section 03, Robert Camerlinck OPTION. DEF 14A, filed 2023-05-22. Section “Grants of Plan-Based Awards for Fiscal Year 2022” · grants of plan-based awards table. View filing ↗
- Section 03, Richard Aguilar RSU. DEF 14A, filed 2023-05-22. Section “Grants of Plan-Based Awards for Fiscal Year 2022” · grants of plan-based awards table. View filing ↗
- Section 03, Richard Aguilar OPTION. DEF 14A, filed 2023-05-22. Section “Grants of Plan-Based Awards for Fiscal Year 2022” · grants of plan-based awards table. View filing ↗
- Section 03, Marlow Hernandez OPTION. DEF 14A, filed 2023-05-22. Section “Grants of Plan-Based Awards for Fiscal Year 2022” · grants of plan-based awards table. View filing ↗
- Section 03, Robert Camerlinck RSU. DEF 14A, filed 2023-05-22. Section “Grants of Plan-Based Awards for Fiscal Year 2022” · grants of plan-based awards table. View filing ↗
- Section 03, David Armstrong RSU. DEF 14A, filed 2023-05-22. Section “Grants of Plan-Based Awards for Fiscal Year 2022” · grants of plan-based awards table. View filing ↗
- Section 03, David Armstrong OPTION. DEF 14A, filed 2023-05-22. Section “Grants of Plan-Based Awards for Fiscal Year 2022” · grants of plan-based awards table. View filing ↗
- Section 03, Robert Camerlinck RSU. DEF 14A, filed 2023-05-22. Section “Grants of Plan-Based Awards for Fiscal Year 2022” · grants of plan-based awards table. View filing ↗
- Section 03, Brian Koppy RSU. DEF 14A, filed 2023-05-22. Section “Grants of Plan-Based Awards for Fiscal Year 2022” · grants of plan-based awards table. View filing ↗
- Section 03, Brian Koppy OPTION. DEF 14A, filed 2023-05-22. Section “Grants of Plan-Based Awards for Fiscal Year 2022” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A. Section “CEO Pay Ratio”. As printed: 114 : 1.
- Section 08, Solomon D. Trujillo. DEF 14A, filed 2023-05-22. Section “Director Compensation”. As printed: 446,175. View filing ↗
- Section 08, Elliot Cooperstone. DEF 14A, filed 2023-05-22. Section “Director Compensation”. As printed: 376,917. View filing ↗
- Section 08, Jacqueline Guichelaar. DEF 14A, filed 2023-05-22. Section “Director Compensation”. As printed: 376,917. View filing ↗
- Section 08, Dr. Lewis Gold. DEF 14A, filed 2023-05-22. Section “Director Compensation”. As printed: 376,917. View filing ↗
- Section 08, Angel Morales. DEF 14A, filed 2023-05-22. Section “Director Compensation”. As printed: 376,917. View filing ↗
- Section 08, Barry S. Sternlicht. DEF 14A, filed 2023-05-22. Section “Director Compensation”. As printed: 376,917. View filing ↗
- Section 08, Kim Rivera. DEF 14A, filed 2023-05-22. Section “Director Compensation”. As printed: 376,917. View filing ↗
- Section 08, Dr. Alan Muney. DEF 14A, filed 2023-05-22. Section “Director Compensation”. As printed: 376,917. View filing ↗
- Section 08, Dr. Marlow Hernandez. DEF 14A, filed 2023-05-22. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Richard Aguilar 2023-05-25. Form 4, filed 2023-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Aguilar 2023-05-25. Form 4, filed 2023-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Aguilar 2023-05-25. Form 4, filed 2023-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Aguilar 2023-05-25. Form 4, filed 2023-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Aguilar 2023-05-25. Form 4, filed 2023-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Aguilar 2023-05-25. Form 4, filed 2023-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Novell 2023-05-31. Form 4, filed 2023-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Armstrong 2023-05-31. Form 4, filed 2023-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marlow Hernandez 2023-05-31. Form 4, filed 2023-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Koppy 2023-05-31. Form 4, filed 2023-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Aguilar 2023-05-31. Form 4, filed 2023-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert Camerlinck 2023-05-31. Form 4, filed 2023-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Armstrong 2023-06-06. Form 4, filed 2023-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Aguilar 2023-06-07. Form 4, filed 2023-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Aguilar 2023-06-08. Form 4, filed 2023-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Aguilar 2023-06-08. Form 4, filed 2023-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Aguilar 2023-06-08. Form 4, filed 2023-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Aguilar 2023-06-09. Form 4, filed 2023-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Aguilar 2023-06-12. Form 4, filed 2023-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacqueline Guichelaar 2023-06-15. Form 4, filed 2023-06-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Angel Morales 2023-06-15. Form 4, filed 2023-06-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dr. Alan Muney 2023-06-15. Form 4, filed 2023-06-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kim Rivera 2023-06-15. Form 4, filed 2023-06-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Solomon D. Trujillo 2023-06-15. Form 4, filed 2023-06-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Aguilar 2023-06-26. Form 4, filed 2023-06-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Aguilar 2023-06-26. Form 4, filed 2023-06-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Aguilar 2023-06-26. Form 4, filed 2023-06-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Aguilar 2023-06-28. Form 4, filed 2023-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Aguilar 2023-06-29. Form 4, filed 2023-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Armstrong 2023-06-30. Form 4, filed 2023-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marlow Hernandez 2023-07-12. Form 4, filed 2023-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark D. Kent 2023-07-12. Form 4, filed 2023-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark D. Kent 2023-07-12. Form 4, filed 2023-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert Camerlinck 2023-08-11. Form 4, filed 2023-08-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eladio Gil 2023-11-10. Form 4, filed 2023-11-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Angel Morales 2023-11-20. Form 4, filed 2023-11-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Angel Morales 2023-11-20. Form 4, filed 2023-11-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Angel Morales 2023-11-20. Form 4, filed 2023-11-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Solomon D. Trujillo 2023-12-07. Form 4, filed 2023-12-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Solomon D. Trujillo 2023-12-07. Form 4, filed 2023-12-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Solomon D. Trujillo 2023-12-07. Form 4, filed 2023-12-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elliot Cooperstone 2023-12-15. Form 4, filed 2023-12-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elliot Cooperstone 2023-12-15. Form 4, filed 2023-12-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elliot Cooperstone 2023-12-15. Form 4, filed 2023-12-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elliot Cooperstone 2023-12-21. Form 4, filed 2023-12-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elliot Cooperstone 2023-12-21. Form 4, filed 2023-12-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elliot Cooperstone 2023-12-22. Form 4, filed 2023-12-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elliot Cooperstone 2023-12-26. Form 4, filed 2023-12-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elliot Cooperstone 2023-12-27. Form 4, filed 2023-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elliot Cooperstone 2023-12-28. Form 4, filed 2023-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elliot Cooperstone 2023-12-29. Form 4, filed 2023-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elliot Cooperstone 2024-01-02. Form 4, filed 2024-01-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elliot Cooperstone 2024-01-03. Form 4, filed 2024-01-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elliot Cooperstone 2024-01-03. Form 4, filed 2024-01-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elliot Cooperstone 2024-01-04. Form 4, filed 2024-01-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elliot Cooperstone 2024-01-05. Form 4, filed 2024-01-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elliot Cooperstone 2024-01-08. Form 4, filed 2024-01-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elliot Cooperstone 2024-01-09. Form 4, filed 2024-01-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elliot Cooperstone 2024-01-10. Form 4, filed 2024-01-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elliot Cooperstone 2024-01-11. Form 4, filed 2024-01-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elliot Cooperstone 2024-01-12. Form 4, filed 2024-01-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elliot Cooperstone 2024-01-12. Form 4, filed 2024-01-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elliot Cooperstone 2024-01-12. Form 4, filed 2024-01-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elliot Cooperstone 2024-01-12. Form 4, filed 2024-01-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elliot Cooperstone 2024-01-17. Form 4, filed 2024-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elliot Cooperstone 2024-01-17. Form 4, filed 2024-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elliot Cooperstone 2024-01-18. Form 4, filed 2024-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elliot Cooperstone 2024-01-22. Form 4, filed 2024-01-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elliot Cooperstone 2024-01-23. Form 4, filed 2024-01-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elliot Cooperstone 2024-01-24. Form 4, filed 2024-01-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elliot Cooperstone 2024-01-25. Form 4, filed 2024-01-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elliot Cooperstone 2024-01-26. Form 4, filed 2024-01-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elliot Cooperstone 2024-01-29. Form 4, filed 2024-01-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elliot Cooperstone 2024-01-30. Form 4, filed 2024-02-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elliot Cooperstone 2024-01-31. Form 4, filed 2024-02-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elliot Cooperstone 2024-02-01. Form 4, filed 2024-02-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark D. Kent 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eladio Gil 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark D. Kent 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark D. Kent 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark D. Kent 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark D. Kent 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark D. Kent 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Angel Morales 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nut Tree Capital Management, LP 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nut Tree Capital Management, LP 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nut Tree Capital Management, LP 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nut Tree Capital Management, LP 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nut Tree Capital Management, LP 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert Camerlinck 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Armstrong 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Solomon D. Trujillo 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Solomon D. Trujillo 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dr. Alan Muney 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Angel Morales 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kim Rivera 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark D. Kent 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nut Tree Capital Management, LP 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-06-22. Item 5.07 · say-on-pay result. As reported: 26.77% (votes for as printed: 120,520,092). View filing ↗
- Section 06, 2022 vote. Form 8-K, filed 2022-05-18. Item 5.07 · say-on-pay result. As reported: 96.78% (votes for as printed: 400,342,807). View filing ↗
- Section 06, 2021 vote. Form 8-K, filed 2021-06-02. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 425,753 + equity 2,658,841 + all other 0 = 3,084,594, summed across the director compensation table rows.
- Apollo Medical Holdings, Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Apollo Medical Holdings's own proxy. As printed: 14,930,231. View filing ↗
- Mednax (MD), Section 10b CEO total. DEF 14A, filed 2026-03-27. CEO total compensation as printed in Mednax (MD)'s own proxy. As printed: 14,140,217. View filing ↗
- The Ensign Group, Section 10b CEO total. DEF 14A, filed 2026-04-02. CEO total compensation as printed in The Ensign Group's own proxy. As printed: 13,804,700. View filing ↗
- Addus HomeCare, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Addus HomeCare's own proxy. As printed: 12,190,449. View filing ↗
- RadNet, Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in RadNet's own proxy. As printed: 12,087,934. View filing ↗
- Teladoc Health, Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Teladoc Health's own proxy. As printed: 11,202,996. View filing ↗
- Encompass Health, Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Encompass Health's own proxy. As printed: 10,297,258. View filing ↗
- Acadia Healthcare, Section 10b CEO total. DEF 14A, filed 2026-03-25. CEO total compensation as printed in Acadia Healthcare's own proxy. As printed: 7,909,463. View filing ↗
- Surgery Partners, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Surgery Partners's own proxy. As printed: 6,083,862. View filing ↗
- U.S. Physical Therapy, Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in U.S. Physical Therapy's own proxy. As printed: 4,468,314. View filing ↗
- Cano Health (subject), Section 10b CEO total. DEF 14A, filed 2023-05-22. CEO total compensation as printed in Cano Health's own proxy. As printed: 4,320,007. View filing ↗
- National HealthCare, Section 10b CEO total. DEF 14A, filed 2026-04-02. CEO total compensation as printed in National HealthCare's own proxy. As printed: 2,685,370. View filing ↗
- CorVel, Section 10b CEO total. DEF 14A, filed 2026-06-26. CEO total compensation as printed in CorVel's own proxy. As printed: 1,285,043. View filing ↗